Literature DB >> 27686116

Use of non-antiretroviral drugs among individuals with and without HIV-infection: a Danish nationwide study.

Line D Rasmussen1, Gitte Kronborg2, Carsten S Larsen3, Court Pedersen1, Jan Gerstoft4, Niels Obel4, Anton Pottegård5.   

Abstract

AIM: We investigated the use of non-antiretroviral drugs in the HIV-infected compared to the general population.
METHODS: From the Danish HIV Cohort Study, we identified all HIV-infected individuals older than 18 years at HIV diagnosis who received care in Denmark through 1995-2013 and reported no injection drug abuse or hepatitis C infection. Population controls were identified from The Danish Civil Registration System and matched on age and gender (5:1). We analyzed the proportion of individuals who redeemed 0-1, 2-4, 5-9, or 10 or more non-antiretroviral drugs. Data were analyzed according to calendar time, age, time from initiation of combination antiretroviral therapy (cART) and stratified by gender, geographical origin and route of HIV transmission. We further analyzed the use of the 25 most used non-antiretroviral drug classes.
RESULTS: We identified 4,928 HIV-infected individuals (median age: 37; 76.4% males). Overall, the HIV-infected population had a higher use of non-antiretroviral drugs compared to the background population. Whereas, the use of non-antiretroviral drugs in the HIV-infected population only changed marginally with time, the use in the background population increased considerably. Thus, use in the HIV-infected population only differed marginally from that of the background population in recent years. This difference was most pronounced in men who have sex with men (MSM).
CONCLUSION: Compared to the background population, HIV infected individuals have increased use of non-antiretroviral drugs. The excess use is mainly observed in MSM and has decreased with calendar time, why it in recent years only differs marginally from that observed in the background population.

Entities:  

Keywords:  HAART; HIV; age-related diseases; multi-morbidity; polypharmacy

Mesh:

Substances:

Year:  2016        PMID: 27686116     DOI: 10.1080/23744235.2016.1212168

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  4 in total

1.  [Cost and factors associated with the prescription of non-antiretroviral drugs among HIV-infected patients under antiretroviral therapy in a reference hospital in Morocco].

Authors:  Hicham Titou; Mohammed Boui; Naoufal Hjira
Journal:  Med Trop Sante Int       Date:  2022-01-21

2.  Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy.

Authors:  Krista J Siefried; Limin Mao; Lucette A Cysique; John Rule; Michelle L Giles; Don E Smith; James McMahon; Tim R Read; Catriona Ooi; Ban K Tee; Mark Bloch; John de Wit; Andrew Carr
Journal:  AIDS       Date:  2018-01-02       Impact factor: 4.177

Review 3.  The challenge of HIV treatment in an era of polypharmacy.

Authors:  David Back; Catia Marzolini
Journal:  J Int AIDS Soc       Date:  2020-02       Impact factor: 5.396

4.  Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis.

Authors:  Mohammed I Danjuma; Oyelola A Adegboye; Ahmed Aboughalia; Nada Soliman; Ruba Almishal; Haseeb Abdul; Mohamad Faisal Hamad Mohamed; Mohamed Nabil Elshafie; Abdulatif AlKhal; Abdelnaser Elzouki; Arwa Al-Saud; Mas Chaponda; Mubarak Arriyo Bidmos
Journal:  Ther Adv Drug Saf       Date:  2022-08-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.